Brain metastasis resection: the impact of fluorescence guidance (MetResect study)

Abstract

OBJECTIVE Maximal resection of brain metastases (BMs) improves both progression-free survival and overall survival (OS). Fluorescein sodium (FL) in combination with the YELLOW 560-nm filter is a safe and feasible method for visualizing residual tumor tissue during BM resection. The authors of this study aimed to show that use of FL would positively influence the volumetric extent of resection (EOR) and thus the survival outcome in patients undergoing BM resection. METHODS Analyzing their institution’s prospective brain tumor registry, the authors identified 539 consecutive patients with BMs (247 women, mean age 62.8 years) by using preoperative high-quality MR images for volumetric analysis. BMs were resected under white light (WL) in 293 patients (54.4%; WL group) and under FL guidance in 246 patients (45.6%; FL group). Sex, age, presurgical Karnofsky Performance Status (KPS), recursive partitioning analysis class, and adjuvant treatment modalities were well balanced between the two groups. Volumetric analysis was performed in a blinded fashion by quantifying pre- and postoperative tumor volume based on gadolinium-enhanced T1-weighted sequences. RESULTS In the FL group, the postoperative tumor volume was significantly smaller (p = 0.01), and hence the quantitative EOR was significantly larger (p = 0.024) and OS was significantly longer (p = 0.0001) (log-rank testing). Multivariate Cox regression modeling showed that age, presurgical KPS, metastasis status, and FL-guided resection are independent prognostic factors for survival. CONCLUSIONS Compared with WL resection, FL-guided BM resection increased resection quality, significantly improved EOR, and prolonged OS.

Hirnmetastasen

“…Eine möglichst komplette Resektion hat sich in einigen Studien als benefitär erwiesen [86,91]. Die Anwendung von Fluoreszein-Natrium als sensitiver intraoperativer Fluoreszenzmarker bei der Hirnmetastasenresektion hat daher in neueren Studien nicht nur eine verbesserte Resektionsgüte erreichen lassen, sondern sich auch auf das Gesamtüberleben positiv ausgewirkt [92,93]. Bei Rezidivmetastasen stellt die chirurgische Resektion in selektierten Fällen, welche durch eine ausreichende anatomische Erreichbarkeit und einen guten Gesamtzustand der Patienten definiert sind, eine valide Therapieoption mit geringer Morbidität und Mortalität dar [94].…”